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Abstract
Introduction: Mammographic density (MD) is one of the strongest known breast cancer risk factors. Estrogen and
progestin therapy (EPT) has been associated with increases in MD. Dense breast tissue is characterized by increased
stromal tissue and (to a lesser degree) increased numbers of breast epithelial cells. It is possible that genetic factors
modify the association between EPT and MD, and that certain genetic variants are particularly important in
determining MD in hormone users. We evaluated the association between MD and 340 tagging single nucleotide
polymorphisms (SNPs) from about 30 candidate genes in hormone metabolism/growth factor pathways among
women who participated in the Norwegian Breast Cancer Screening Program (NBCSP) in 2004.
Methods: We assessed MD on 2,036 postmenopausal women aged 50 to 69 years using a computer-assisted
method (Madena, University of Southern California) in a cross-sectional study. We used linear regression to
determine the association between each SNP and MD, adjusting for potential confounders. The postmenopausal
women were stratified into HT users (EPT and estrogen-only) and non-users (never HT).
Results: For current EPT users, there was an association between a variant in the prolactin gene (PRL; rs10946545) and
MD (dominant model, Bonferroni-adjusted P (Pb) = 0.0144). This association remained statistically significant among
current users of norethisterone acetate (NETA)-based EPT, a regimen common in Nordic countries. Among current
estrogen-only users (ET), there was an association between rs4670813 in the cytochrome P450 gene (CYP1B1) and MD
(dominant model, Pb = 0.0396). In never HT users, rs769177 in the tumor necrosis factor (TNF) gene and rs1968752 in the
region of the sulfotransferase gene (SULT1A1/SULT1A2), were significantly associated with MD (Pb = 0.0202; Pb = 0.0349).
Conclusions: We found some evidence that variants in the PRL gene were associated with MD in current EPT and
NETA users. In never HT users, variants in the TNF and SULT1A1/SULT1A2 genes were significantly associated with
MD. These findings may suggest that several genes in the hormone metabolism and growth factor pathways are
implicated in determining MD.
Introduction
Mammographic density (MD) is the radiodense or white
area on a mammogram. MD reflects the amount of
fibrous stroma and epithelium in the breast [1,2]. MD
has been associated with stromal growth factors [3], as
well as the number of epithelial cells, but not with
increased epithelial cell proliferation [4].
MD is one of the strongest known breast cancer risk fac-
tors [5]. Women with MD of 75% or greater have a risk of
breast cancer that is four to five times higher than women
of the same age with little or no density (≤ 5%) [6].
Several studies have suggested that MD is at least par-
tially inherited. Studies of twins suggest that genetic
factors explain 30 to 60% of the variation in MD [7-9].
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A number of studies have assessed the role of genetic
variants identified through genome-wide association
studies (GWAS) of breast cancer on MD [10,11], but
the results of these studies are inconsistent. A recent
meta-analysis of GWAS on MD identified one variant
(rs10995190) in the zinc finger protein 365 gene
(ZNF365) [12], but this variant only explained about
0.5% of the variance in MD. Thus, a large proportion of
the variation is yet to be explained.
MD decreases with older age and menopause [13], and
increases in postmenopausal women randomized to hor-
mone treatment [14]. Parity [15] and early age at first
full-term pregnancy are both associated with reduced
MD [16]. Because of the clear role of hormones on MD,
it has been suggested that genes involved in pathways
that regulate steroid hormone synthesis and metabolism,
hormone receptors, or genes in growth factor pathways
may play a role. However, genetic association studies of
candidate pathways either involving hormones or growth
factors, have been few so far [17,18]. Many studies have
focused on selected variants, and these have not yielded
consistent results [19-28]. It seems likely that such var-
iants could determine how women metabolize hormone
therapy (HT), or determine the downstream effect of
hormones, and therefore some variants would only be
important in women taking HT. Few of the studies so far
have examined this association according to HT status
[18,21].
Therefore, we decided to investigate which genetic
variants were the most important in explaining MD in
HT users, and whether the association between genetic
variants and MD was modified statistically by HT use.
We evaluated the association between MD and 340 sin-
gle nucleotide polymorphisms (SNPs) from about 30




Characteristics of the study participants and details about
the study have previously been described [29-31]. Women
selected for the study had attended the Norwegian Breast
Cancer Screening Program (NBCSP) at least once. This
national screening program invites all women aged 50 to
69 years to undergo a mammographic examination every
two years. The attendance rate is 76.2% [32].
A questionnaire on various breast cancer risk factors,
enclosed within the NBCSP invitation, was sent to a
random sample of 17,050 women living in the counties
of Oslo, Akershus and Hordaland in 2004. Menstrual
and reproductive history, use of oral contraceptive and
menopausal hormonal therapy, family history of breast
cancer, current weight and height were assessed by the
standardized questionnaire. A total of 12,056 (71%) of
the invited women attended the screening program and
7,941 (66%) returned a completed questionnaire.
A subset (7,174) of the 7,941 women who had com-
pleted the health questionnaire was asked to complete a
food frequency questionnaire and to provide us with two
buccal swabs. Of these, 3,484 women (49%) returned the
dietary questionnaire and 3,728 returned buccal swabs.
We requested mammograms from the various radiologi-
cal facilities and we focused the requests on mammo-
grams from women who had completed a food frequency
questionnaire and had had a screen film mammography
in 2004. About 300 women from Oslo had undergone
digital mammography. These women were not included
in the current study as assessments from digital images
tend to yield somewhat low percent MD compared with
digitized screen film mammograms.
We obtained information on HT use and analog
screening mammograms from the year 2004 on 2,876
women. Of these, 124 women were excluded for the fol-
lowing reasons; 17 women had had a previous cancer
(12 = breast, 5 = ovarian), the breast area could not be
determined on mammograms from 3 women, 28 had
incomplete data on age, and 73 incomplete data on
body mass index (BMI) (height = 46/weight = 67).
Three women were excluded because they used proges-
terone-only HT. After the exclusions, a total of 2,752
women with mammograms and HT data were left for
analysis. All the participants signed an informed consent
and the study was approved by the Regional Ethics
Committee and the Norwegian Data Inspectorate.
Mammographic density analysis
Mammograms (left craniocaudal) were scanned using a
high-resolution Kodak Lumisys 85 scanner with auto-
matic feeder (Kodak, Rochester, NY, USA). Computer-
assisted readings of absolute areas of dense and non-
dense tissues, as well as percent density, were performed
using the Madena software [33]. This method provides a
continuous measure of density and a separate estimate of
the absolute areas of dense and non-dense tissues. Only
analog mammograms were included due to concern that
the digitally obtained images would not yield comparable
density readings. The density assessments were per-
formed by an experienced reader (G.U.), whereas a
research assistant trained by G.U. conducted the breast
area measurements. Both readers were blinded to all sub-
ject characteristics. Percent MD was calculated by divid-
ing the absolute breast density by the total breast area
and multiplying it by 100. Some suggest that absolute
density is the optimal method [34], but the majority of
the studies on MD have used percent density [6], and we
therefore limited these results to percent MD.
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DNA collection and extraction
Three thousand seven hundred and twenty-eight (3,728)
women returned buccal swabs out of which 3,317 were
genotyped. Of these, 241 women had to be excluded
due to a sample call rate < 80%, yielding 3,076 women.
Of these, we had risk factor information and mammo-
grams collected in 2004 on 2,397 women. DNA was
extracted from buccal swabs using standard modified
protocol for the QIAamp DNA blood kit (Qiagen,
Valencia, CA, USA).
Selection of SNPs
For AR, COMT, CYP1A1/CYP1A2, CYB1B1, ESR2,
HSD17B1, IGFBP1/IGFBP3, IL6, PGR, PPARG, PRL,
SULT1A1/SULT1A2, SULT1E1, TGFB1, TNF and VEGF,
we selected tag SNPs to capture the genetic variation in
each gene. We selected linkage disequilibrium tagging
SNPs across each gene, from 20 kb upstream of 5’
untranslated region (UTR) to 10 kb downstream of the
3’ UTR. Because this study shared an analysis platform
with a study of Chinese women, HapMap Caucasians of
European descent (CEU) data (release 24) [35] and Hap-
Map Han Chinese in Beijing (CHB) data (release 24), as
well as the Snagger [36] or modified Tagger approach
were used to capture all common SNPs (minor allele
frequency ≥ 5%) in Caucasians or Chinese with minimum
pair wise r2 > 0.8. For, ADH1C, AKR1C4, CSHL1,
CYP17A1, CYP19A1, ESR1, FGFR2, GHRHR,
HCV3289988, HSD3B1/HSD3B2, POU5F1, PRLR, SHBG
and SRD5A2, we selected one or a few SNP(s) of interest
for each gene (Table 2).
Genotyping of SNPs
Genotyping was done using an Illumina BeadLab System
(Illumina Inc., San Diego, CA, USA) and GoldenGate™
Genotyping technology in the University of Southern Cali-
fornia Genomics Center. Samples were run in a 96-well
format using Illumina Sentrix Array technology on a Bea-
dArray Reader. BeadStudio Software (version 3.0.9) with
Genotyping Module (version 3.0.27) (Illumina) was used
for analyzing scanned samples. The SNPs with < 85% call
rates were excluded: this resulted in the exclusion of 4% of
SNPs. The genotyping concordance rate based on 41
duplicate samples was 84%. Out of 340 SNPs in the hor-
mone metabolism and growth factor pathways, 18 SNPs
departed from Hardy-Weinberg equilibrium (HWE) (P <
0.001), leaving 322 SNPs for further analysis. None of
these excluded 18 SNPs were associated with MD regard-
less of the hormone use status (data not shown).
Menopausal status and HT use
The classification of postmenopausal women was limited
by our questionnaire where women were asked if they
had undergone a) complete cessation of menstruation of
at least six months b) previous bilateral oophorectomy c)
hysterectomy without bilateral oophorectomy d) used
HT before menopause. Out of the 2,397 women, we
excluded 342 pre- and perimenopausal women. We also
excluded 19 women who had undergone simple hyster-
ectomy without bilateral oophorectomy since these
women could not be classified on menopausal status.
Our final sample size was 2,036 postmenopausal women.
Excluding women with menopause within the past year
(N = 177) yielded essentially unchanged results, and did
not alter the order of the most important SNPs (results
not shown). We therefore present analyses using the six
month definition of menopause.
HT use was assessed by asking two questions about 1)
ever use of HT with a proposed list of HT preparations
and 2) current use of HT. If a woman had used the spe-
cified HT for more than three months at the time of
completing the questionnaire, she was considered a cur-
rent user. A woman could have used both estrogen-only
(ET) and combined estrogen and progestin therapies
(EPT) in her lifetime, but only one of these currently.
Current EPT users were subdivided further into nor-
ethisterone acetate (NETA) regimen users or non-
NETA users.
Statistical analyses
We used multivariate linear regression to examine the
relation between percentage MD and SNPs. The MD
variable was treated in a continuous manner, without
any transformations, as the model’s residuals satisfied
the normality and homoscedasticity assumptions. We
adjusted all analyses for age at screening (continuous)
and BMI (kg/m2, continuous).
We ran these analyses on both additive and dominant
models. However, because the results were largely simi-
lar between the two genetic models, and few women
were homozygote for the variants of many SNPs, we
only present the dominant model (results available upon
request). We conducted analyses, with and without Bon-
ferroni adjustments for multiple comparisons (the num-
ber of SNPs per gene) within each stratum defined by
hormone use. We also ran a test for heterogeneity
between HT users and non-users and present the P
values for this interaction (Pint). In the results section,
we specifically comment on results where the stratum-
specific two-sided P values are less than 0.01 and the
Bonferroni-adjusted P values (Pb) are less than 0.05.
We estimated least squares means (marginal means)
on MD and all our explanatory variables among never,
current and past EPT users. Least squares means are
the group mean after having controlled for a covariate
(age and BMI). We subdivided HT users into ET or
EPT. EPT users were further subdivided into NETA
users or non-users.
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Results
Characteristics of the study population by strata of EPT
use (no, past and current) are shown in Table 1. As pre-
viously described, MD was higher in current EPT users
than in past or never users [31]. There were statistically
significant differences in percent density, BMI and in
age at screening between never, past and current EPT
users. Table 2 shows the number of SNPs successfully
genotyped for each gene we investigated.
Among all postmenopausal women, there was no
association between SNPs and MD after Bonferroni
adjustments (Table S1 in Additional file 1). Among
postmenopausal never HT users, there was an associa-
tion between MD and a variant in the tumor necrosis
factor (TNF) gene (rs769177; Pb = 0.020), and with a
variant in the sulfotransferase (SULT1A1/SULT1A2)
gene (rs1968752; Pb = 0.035) (Table S2 in Additional
file 2).
For postmenopausal current ET users (Table 3) there
was an association between a variant in the cytochrome
P450 (CYP1B1) gene (rs4670813, Pb = 0.0396) and MD.
In current EPT users (Table 4) a variant in the prolactin
(PRL) gene (rs10946545, Pb = 0.0144) was significantly
associated with MD. The results from the analysis of all
SNPs in all women combined, and in ET users and EPT
users separately, as well as the interaction tests are
shown in Table S3 in Additional file 3. Mean percent
mammographic density was highest in homozygous
wild-type carriers of PRL rs10946545 who currently
used EPT (Figure 1).
NETA is an EPT-based regimen common in Nordic
countries. The results remained statistically significant
when analyses were restricted to NETA users (results
not shown).
When we adjusted for parity (parous/nulliparous), the
three PRL SNPs that were significant in the EPT users
remained statistically significant before Bonferroni cor-
rection (rs10946545 P = 0.0028/rs2744117 P = 0.0218/
rs1156546 P = 0.0345). None of these were statistically
significant after Bonferroni adjustment. In the interac-
tion test between these three SNPs and EPT, two of the
three SNPs remained statistically significant (rs10946545
Pint = 0.0051/rs1156446 Pint = 0.0317) after adjustment
for parity.
Discussion
In this study of postmenopausal Norwegian women, we
found that MD was associated with several variants in
growth factor and hormone metabolism genes (PRL,
CYP1B1, SULT1A1/SULT1A2 and TNF). However, dif-
ferent variants appeared to be important depending on
the women’s HT use.
There have been a number of studies of genetic varia-
tions and MD [18-28]. However, few studies have exam-
ined this association by HT use or tested the interaction
with hormone use. Below, we discuss our results by sub-
group of HT use.
Among postmenopausal never HT users (N = 1,008),
we found associations between MD and variants in the
TNF and the SULT1A1/SULT1A2 genes. TNF refers to
a group of cytokines that are important in inflammation,
as well as in growth, differentiation and cell death. TNF
has been implicated in tumor regression [37,38], and
there is some evidence that TNF genetic variants are
associated with breast cancer risk [39]. Our findings are
consistent with this. As far as we know, no other study
has examined the association between TNF variants and
MD. One cross-sectional study on postmenopausal
American women found no statistically significant asso-
ciations between circulating TNF levels and MD after
adjustment for BMI [40]. However, the study did not
take HT use into account. In our study, one TNF var-
iant was important in never users and in all women, the
latter association possibly because more than half of the
women were never users. However, this variant was not
important in EPT users, nor was the interaction between
never users and EPT users statistically significant. Two
other TNF variants showed statistical significance in the
interaction between never users and EPT users, but not
after Bonferroni adjustments. The exact role of TNF
genetic variation on mammographic density is thus
unclear, however, if inflammation is an important aspect
Table 1 Characteristics of no, past and current estrogen and progestin therapy (EPT) users (N = 2,036).
No EPT (N = 1,176) Past EPT (N = 612) Current EPT (N = 248)
N Mean1 SE2 N Mean1 SE2 N Mean1 SE2 P3
Mammographic density (%) 1,176 17.07 0.46 612 18.99 0.45 248 23.34 0.51 0.0001
Age at screening (years) 1,176 58.19 0.18 612 59.22 0.15 248 57.33 0.15 0.0001
Body mass index (kg/m2) 1,176 25.44 0.13 612 24.91 0.10 248 24.15 0.11 0.0001
Age at menarche (years) 1,169 13.16 0.04 607 13.36 0.04 246 13.31 0.04 0.1025
Age at first pregnancy (years) 1,049 21.75 0.25 540 22.3 0.24 225 22.28 0.24 0.3602
Number of children 1,114 2 0.03 587 2 0.03 239 2 0.03 0.7252
Education (years) 1,164 12.75 0.10 605 13.01 0.10 245 12.85 0.10 0.2807
1Adjusted for age and BMI, 2standard error, 3analysis of variance.
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Table 2 List of genes on single nucleotide polymorphisms (SNPs) genotyped and tagging SNP approach.































*See methods for details on how tagging SNPs were selected.
Table 3 Top twenty single nucleotide polymorphism (SNPs) in postmenopausal current estrogen-only users (N = 78)
that showed the strongest heterogeneity between never hormone therapy users and estrogen-only users.
Gene SNP SNPs per gene Alleles WW WV+VV Beta1 SE P1 Pb2 Pint3
PPARG rs1175543 32 A/G 42 36 -9.80 3.00 0.0017 0.0535 0.0028
CYP1B1 rs4670813 17 G/A 25 53 -9.99 3.17 0.0023 0.0396 0.0059
CYP1B1 rs162550 17 G/C 44 34 8.19 3.11 0.0103 0.1753 0.0068
ESR2 rs1256063 29 G/A 65 13 12.27 4.00 0.0030 0.0868 0.0069
IGFBP1/IGFBP3 rs1496497 29 G/A 47 31 -8.08 3.13 0.0119 0.3464 0.0155
IL6 rs6949149 19 G/T 70 8 -12.82 4.97 0.0119 0.2256 0.0206
TGFB1 rs8179181 11 A/T 48 30 7.91 3.16 0.0144 0.1579 0.0214
ESR1 rs2295190 12 G/T 51 27 -6.45 3.36 0.0590 0.7086 0.0293
PPARG rs1151996 32 A/C 36 42 -7.18 3.11 0.0236 0.7554 0.0520
CYP1B1 rs1625 17 T/G 49 29 6.74 3.25 0.0418 0.7098 0.0557
TGFB1 rs1982072 11 A/T 35 43 -6.32 3.17 0.0498 0.5478 0.0577
CYP1A1/CYP1A2 rs11072507 13 C/G 39 39 7.26 3.24 0.0281 0.3656 0.0578
CYP1B1 rs162557 17 G/A 47 31 6.05 3.21 0.0635 1.0791 0.0622
IGFBP1/IGFBP3 rs10241749 29 A/G 49 29 7.10 3.35 0.0375 1.0878 0.0657
PPARG rs2120825 32 T/G 56 22 8.12 3.42 0.0201 0.6421 0.0733
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of breast cancer development, then it seems reasonable
that TNF variants may play a role.
Sulfotransferase 1A1 and 1A2 are enzymes that are
encoded by the SULT1A1 and SULT1A2 genes. Sulfo-
transferase enzymes catalyze hormones, drugs and xeno-
biotic compounds [41]. In a review of 18 studies of
SNPs located in genes of the estrogen pathway,
SULT1A1/SULT1A2 did not show any association with
MD on the overall study population [42]. In a study on
American premenopausal women, it was concluded that
SNPs in SULT1A1 locus may influence percent density
[43]. In our study, SULT1A1/SULT1A2 was important
in never users, but not in HT users. A possible explana-
tion could be that the SULT variants interact with expo-
sures important for MD in women not using hormones,
although it may also be a chance finding.
There were few current ET users in our study (N =
78), but among them we observed a negative association
between MD and rs4670813 (CYP1B1). CYP1B1 belongs
to the cytochrome P450 super family of enzymes and is
important in the metabolism of estrogen that may affect
breast cancer risk. CYP1B1 catalyzes formation of
potentially carcinogenic catechol estrogens and forms 4-
hydroxylation of estrone [44]. CYP1B1 expression levels
have also been reported to be lower in tumors than in
adjacent benign tissue [45], suggesting that a key factor
in breast carcinogenesis is not increased 4-hydroxylation
but reduced estradiol metabolism. Thus, both increased
and reduced CYP1B1 activity has been hypothesized to
be associated with breast cell proliferation. In the
SWAN study, CYP1B1; rs162555 was associated with a
higher MD in pre- and early perimenopausal women
Table 3 Top twenty single nucleotide polymorphism (SNPs) in postmenopausal current estrogen-only users (N = 78)
that showed the strongest heterogeneity between never hormone therapy users and estrogen-only users. (Continued)
COMT rs12627876 29 C/T 77 1 26.61 13.83 0.0582 1.6881 0.0827
CYP1A1/CYP1A2 rs2606345 13 A/C 38 40 7.00 3.09 0.0263 0.3415 0.0886
IGFBP1/IGFBP3 rs4619 29 A/G 28 50 -6.51 3.31 0.0531 1.5400 0.0950
HSD3B1/HSD3B2 rs6428828 3 A/T 38 40 5.77 3.08 0.0650 0.1951 0.0954
PRL rs1123886 34 T/C 36 42 6.22 3.17 0.0533 1.8109 0.2058
1From linear regression models using percent mammographic density as the outcome variable. Adjusted for age and BMI in a dominant model of inheritance.
See Table S2 in Additional file 2 for the stratum-specific results in never HT users. 2Bonferroni-adjusted P values. 3P for interaction for ET vs. never HT users in all
postmenopausal women (N = 2,036).
Table 4 Top twenty single nucleotide polymorphisms (SNPs) that showed the strongest heterogeneity in association
between never hormone therapy users (N = 1,008) and postmenopausal current estrogen and progestin users (N =
248), by P for interaction.
Gene SNP SNPs per gene Alleles WW WV+VV Beta SE P1 Pb2 Pint3
PRL rs10946545 34 G/A 219 29 10.86 3.04 0.0004 0.0144 0.0008
ESR2 rs12434245 29 C/T 216 32 -8.09 2.94 0.0063 0.1839 0.0034
TNF rs3093553 15 T/G 228 20 -9.86 3.63 0.0070 0.1050 0.0046
CYP1A1/CYP1A2 rs3743 13 G/C 233 15 -9.79 4.16 0.0194 0.2524 0.0061
TNF rs3093662 15 A/G 225 23 -8.53 3.42 0.0133 0.2002 0.0064
TNF rs4947324 15 C/T 214 34 -8.53 2.89 0.0035 0.0520 0.0154
PRL rs2744117 34 G/T 212 36 7.97 2.80 0.0048 0.1633 0.0206
ESR2 rs7159462 29 C/T 214 34 -6.61 2.87 0.0222 0.6447 0.0248
PRL rs1156546 34 A/C 163 85 4.77 2.09 0.0230 0.7812 0.0249
SHBG rs6258 13 C/T 246 2 23.25 11.09 0.0370 0.4815 0.0345
ESR2 rs10137185 29 C/T 209 39 -5.20 2.73 0.0575 1.6684 0.0425
PGR rs569857 32 T/A 217 31 -5.69 3.02 0.0603 1.9306 0.0434
PPARG rs4279078 32 G/A 203 45 6.09 2.58 0.0190 0.6082 0.0442
PPARG rs2960420 32 C/G 111 137 -4.60 1.99 0.0219 0.6997 0.0458
VEGF rs699946 21 A/G 159 89 -3.96 2.08 0.0587 1.2333 0.0719
PGR rs7106686 32 G/A 188 60 -4.46 2.32 0.0559 1.7873 0.0854
PRL rs9358533 34 C/T 207 41 6.45 2.66 0.0159 0.5413 0.0927
PGR rs507141 32 G/A 185 63 4.40 2.28 0.0550 1.7594 0.1431
PGR rs5181 32 C/G 208 40 -5.58 2.72 0.0411 1.3164 0.1753
PRL rs1205960 34 C/T 140 108 -3.86 2.01 0.0559 1.8994 0.1765
1From linear regression models using percent mammographic density as the outcome variable. Adjusted for age and BMI in a dominant model of inheritance.
2Bonferroni-adjusted P values. 3P for interaction for EPT vs. never HT users in all postmenopausal women (N = 2,036).
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[27]. In a cross-sectional study on postmenopausal
women who participated in two randomized, double-
blind, placebo-controlled studies, there was no evidence
of an association between MD and genotypes in women
randomized to ET [21]. In a case-control study of
American postmenopausal women (PACE), the authors
found an association between CYP1B1; rs1056827 and
breast cancer risk in ever EPT users [46]. As long as the
functional role of rs4670813 is unknown, the mechan-
ism behind our observed negative association between
MD and rs4670813 remains elusive.
The most significant findings in our study were the
association between a variant in PRL gene (rs10946545)
and MD in current EPT users (N = 248) and in users of
NETA-based EPT. Prolactin, also known as luteotropic
hormone, is a protein that in humans is encoded by the
PRL gene [47]. It is produced by the pituitary gland and
in lesser amounts by several other tissues, including
breast tissue. Prolactin plays an important role in breast
development, differentiation and lactation [48], but may
also have procarcinogenic effects [49,50]. There are pro-
lactin receptors in both normal breast tissue and in
breast tumor tissue [51-53]. Our findings are consistent
with the results in a case-control study on Polish
women. In that study, two SNPs (rs7718468 and
rs13436213) in the prolactin receptor (PRLR) gene were
associated with breast cancer risk in postmenopausal
women [54]. In our study, we found this association in
current EPT users. Adjustments for parity did not oblit-
erate the association, and the association was observed
in strata of both parous and nulliparous women (results
not shown). How parity and prolactin interact with hor-
mones important for breast epithelial proliferation is not
yet clear, but may be important in breast cancer devel-
opment. Parity has previously been found to primarily
reduce risk of estrogen receptor and progestin receptor
positive (ER+PR+) cancer, while breastfeeding reduces
risk of both ER+ PR+ and ER-PR- cancer [55]. Whether
PRL plays a role in this interaction is unknown. When
we adjusted for parity, the SNPs in the PRL gene
remained statistically significant, suggesting that the
number of children does not attenuate the association
between variants in PRL and MD.
In a case-control study within the prospective Nurses’
Health Study, plasma level of prolactin was positively
associated with the risk of breast cancer [56]. Data from
a randomized, placebo-controlled study suggested that
EPT use in postmenopausal women increased the PRL
concentration [57]. However, that study did not examine
the role of genetic variations. In the first family linkage
study on MD, a locus on chromosome 5p was associated
with MD, and the PRLR is at a region surrounding this
locus [28]. Taken together, current data suggest that
both PRL and PRLR may be important for MD.
Figure 1 Mean percent mammographic density by prolactin (PRL) rs10946545 genotype and hormone therapy use. A figure that
presents mean percent mammographic density by the PRL gene (rs10946545) in women with two wild-type alleles and with one or two variant
(minor) alleles in never hormone therapy (HT) users and in current estrogen and progestin therapy (EPT) users.
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Summing up, our results indicate that a number of
genetic variants that determine how women metabolize
HT, or how HT exerts its effect on the breast, might be
associated with MD in HT users.
Strengths and weaknesses
There are several strengths of this study. First, our study
investigated the association between genetic variations in
the hormone metabolism and growth factor pathways and
MD in HT users and non-users, and in ET and EPT users.
Not many other studies have investigated these relations.
Another strength of this study is the sample size (N =
2,036), and that it is population based. A third strength is
that we had risk factor information available, although we
only used age at screening, height/weight, hormone use
and parity in this analysis. A weakness of the study is that
we were not able to identify a study with similar types of
hormone users, and thus have not been able to replicate
our findings in another study. Further validation is there-
fore important. Another weakness is that we had only
information on current height and weight (2004). We
obtained the mammograms from three different screening
facilities with different equipment and personnel. Even
though the mammography procedures are standardized
within the NBCSP, there is variation between radiogra-
phers on how to position and compress the breasts.
Nevertheless, these potential sources of errors are not
likely to be associated with genotype and would be
expected to give a bias toward the null. We did not per-
form longitudinal studies, nor studies to establish the
functional consequences of the SNPs, thereby restricting
the ability to assess causation. To adjust for multiple com-
parisons we used Bonferroni adjustment. This is rather
conservative, and we may thus have failed to identify other
stratum-specific estimates that are biologically relevant.
Conclusions
We found some evidence that variants in the PRL gene
were associated with MD in current EPT and NETA
users. Variants in TNF and SULT1A1/SULT1A2 were
associated with MD in never HT users. These findings
may suggest that several genes in the hormone metabo-
lism/growth factor pathways are implicated in determining
MD. Some genetic variants in combination with specific
HT may increase MD in susceptible women. Exploring
the functional role of the SNPs associated with MD will
further clarify the biological mechanisms involved.
Additional material
Additional file 1: Table S1. Table S1 in Additional file 1. The
frequency and the minor allele frequency (MAF) of the single
nucleotide polymorphisms (SNPs) evaluated and association with
percent mammographic density (Beta, se, P) for all postmenopausal
women (N = 2,036). This is a list of all the SNPs and the frequency and
minor allele frequency in the population for all postmenopausal women.
Additional file 2: Table S2. Table S2 in Additional file 2. Top twenty
single nucleotide polymorphisms (SNPs) associated with percent
mammographic density in postmenopausal never hormone therapy
users (N = 1,008). This is a table of the top SNPs associated with MD in
never HT users, sorted by P values.
Additional file 3: Table S3. Table S3 in Additional file 3. P values
from analysis of all single nucleotide polymorphisms (SNPs) in all
postmenopausal women combined, among estrogen therapy (ET)
users only, and among combined estrogen and progestin therapy
(EPT) users only, as well as results from interaction tests of ET users
and EPT users versus never hormone therapy (HT) users. A table
that presents the P values for all women and the different strata in
addition to P for interaction values between HT users and non-users.
Abbreviations
BMI: body mass index; CYP1B1: cytochrome P450 gene; EPT: estrogen and
progestin therapy; ET: current estrogen-only users; GWAS: genome-wide
association studies; HWE: Hardy-Weinberg equilibrium; HT: hormone therapy;
MD: mammographic density; NBCSP: the Norwegian Breast Cancer Screening
Program; NETA: norethisterone acetate; Pb: Bonferroni-adjusted P; PRL:
prolactin gene; PRLR: prolactin receptor; SNP: single nucleotide
polymorphism; SULT1A1/SULT1A2: sulfotransferase gene; TNF: tumor necrosis
factor gene; UTR: untranslated region; ZNF365 gene: zinc finger protein 365.
Acknowledgements
This work was supported by grants from the Norwegian Cancer Society
(171743 - PR-2009-0210).
Author details
1Department of Nutrition, University of Oslo, P.O. Box 1046, Blindern, 0316
Oslo, Norway. 2Department of Preventive Medicine, Keck School of Medicine,
University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA
90089, USA. 3Cancer Registry of Norway, P.O. Box 5313, Majorstuen, 0304
Oslo, Norway. 4Department of Medical Epidemiology and Biostatistics,
Karolinska Institutet, P.O. Box 281, SE-17177 Stockholm, Sweden. 5Oslo and
Akershus University College of Applied Sciences, P.O. Box 4, St. Olavs plass,
0130 Oslo, Norway. 6The Gade Institute, Section for Pathology, University of
Bergen, P.O. Box 7804, NO-5020 Bergen, Norway.
Authors’ contributions
ME carried out the statistical analyses and drafted the manuscript. EL
participated in the genetic data cleaning, analysis and interpretation of data
and manuscript revision. EC provided expertise in the statistical program (SAS)
and cleaned all the hormone therapy variables. AO took part in the genetic
statistical analyses in SAS. DVDB coordinated tagging SNP selection and
performed the genotyping. SQ participated in data cleaning and acquisition of
data. LA, SH and TG contributed to the analysis and interpretation of data. GU
participated in the design of the study and in SNP selection, and supervised the
analysis and manuscript preparation. All authors have read and approved the
final manuscript and revised it critically for important intellectual content.
Competing interests
The authors declare that they have no competing interests.
Received: 16 March 2012 Revised: 7 August 2012
Accepted: 30 August 2012 Published: 24 October 2012
References
1. Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S: Breast tissue
composition and susceptibility to breast cancer. J Natl Cancer Inst 2010,
102:1224-1237.
2. Byng JW, Yaffe MJ, Jong RA, Shumak RS, Lockwood GA, Tritchler DL,
Boyd NF: Analysis of mammographic density and breast cancer risk from
digitized mammograms. Radiographics : a review publication of the
Radiological Society of North America, Inc 1998, 18:1587-1598.
Ellingjord-Dale et al. Breast Cancer Research 2012, 14:R135
http://breast-cancer-research.com/content/14/5/R135
Page 8 of 10
3. Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E, Khokha R,
Boyd NF: Growth factors and stromal matrix proteins associated with
mammographic densities. Cancer Epidemiol Biomarkers Prev 2001,
10:243-248.
4. Hawes D, Downey S, Pearce CL, Bartow S, Wan P, Pike MC, Wu AH: Dense
breast stromal tissue shows greatly increased concentration of breast
epithelium but no increase in its proliferative activity. Breast Cancer Res
2006, 8:R24.
5. Vachon CM, van Gils CH, Sellers TA, Ghosh K, Pruthi S, Brandt KR,
Pankratz VS: Mammographic density, breast cancer risk and risk
prediction. Breast Cancer Res 2007, 9:217.
6. McCormack VA, dos Santos Silva I: Breast density and parenchymal
patterns as markers of breast cancer risk: a meta-analysis. Cancer
Epidemiol Biomarkers Prev 2006, 15:1159-1169.
7. Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR,
Giles GG, Tritchler D, Chiarelli A, Yaffe MJ, Hopper JL: Heritability of
mammographic density, a risk factor for breast cancer. N Engl J Med
2002, 347:886-894.
8. Pankow JS, Vachon CM, Kuni CC, King RA, Arnett DK, Grabrick DM, Rich SS,
Anderson VE, Sellers TA: Genetic analysis of mammographic breast
density in adult women: evidence of a gene effect. J Natl Cancer Inst
1997, 89:549-556.
9. Ursin G, Lillie EO, Lee E, Cockburn M, Schork NJ, Cozen W, Parisky YR,
Hamilton AS, Astrahan MA, Mack T: The relative importance of genetics
and environment on mammographic density. Cancer Epidemiol Biomarkers
Prev 2009, 18:102-112.
10. Lee E, Haiman CA, Ma H, Van Den Berg D, Bernstein L, Ursin G: The role of
established breast cancer susceptibility loci in mammographic density in
young women. Cancer Epidemiol Biomarkers Prev 2008, 171:258-260.
11. Tamimi RM, Cox D, Kraft P, Colditz GA, Hankinson SE, Hunter DJ: Breast
cancer susceptibility loci and mammographic density. Breast Cancer Res
2008, 10:R66.
12. Lindstrom S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, Brown J,
Leyland J, Audley T, Wareham NJ, Loos RJ, Paterson AD, Rommens J,
Waggott D, Martin LJ, Scott CG, Pankratz VS, Hankinson SE, Hazra A,
Hunter DJ, Hopper JL, Southey MC, Chanock SJ, Silva IdS, Liu J, Eriksson L,
Couch FJ, Stone J, Apicella C, Czene K, et al: Common variants in ZNF365
are associated with both mammographic density and breast cancer risk.
Nat Genet 2011, 43:185-187.
13. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G:
Postmenopausal hormone therapy and change in mammographic
density. J Natl Cancer Inst 2003, 95:30-37.
14. McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED,
Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM,
Hulka BS, Women’s Health Initiative Mammogram Density Study
Investigators: Estrogen-plus-progestin use and mammographic density in
postmenopausal women: Women’s Health Initiative randomized trial.
J Natl Cancer Inst 2005, 97:1366-1376.
15. Dite GS, Gurrin LC, Byrnes GB, Stone J, Gunasekara A, McCredie MR,
English DR, Giles GG, Cawson J, Hegele RA, Chiarelli AM, Yaffe MJ, Boyd NF,
Hopper JL: Predictors of mammographic density: insights gained from a
novel regression analysis of a twin study. Cancer Epidemiol Biomarkers
Prev 2008, 17:3474-3481.
16. Butler LM, Gold EB, Greendale GA, Crandall CJ, Modugno F, Oestreicher N,
Quesenberry CP Jr, Habel LA: Menstrual and reproductive factors in
relation to mammographic density: the Study of Women’s Health Across
the Nation (SWAN). Breast Cancer Res Treat 2008, 112:165-174.
17. Kelemen LE, Sellers TA, Vachon CM: Can genes for mammographic
density inform cancer aetiology? Nat Rev Cancer 2008, 8:812-823.
18. Lee E, Ingles SA, Van Den Berg D, Wang W, Lavallee C, Huang MH,
Crandall CJ, Stanczyk FZ, Greendale GA, Ursin G: Progestogen levels,
progesterone receptor gene polymorphisms, and mammographic
density changes: results from the Postmenopausal Estrogen/Progestin
Interventions Mammographic Density Study. Menopause 2012, 19:302-310.
19. Haiman CA, Bernstein L, Berg D, Ingles SA, Salane M, Ursin G: Genetic
determinants of mammographic density. Breast Cancer Res 2002, 4:R5.
20. Haiman CA, Hankinson SE, De Vivo I, Guillemette C, Ishibe N, Hunter DJ,
Byrne C: Polymorphisms in steroid hormone pathway genes and
mammographic density. Breast Cancer Res Treat 2003, 77:27-36.
21. Lord SJ, Mack WJ, Van Den Berg D, Pike MC, Ingles SA, Haiman CA,
Wang W, Parisky YR, Hodis HN, Ursin G: Polymorphisms in genes involved
in estrogen and progesterone metabolism and mammographic density
changes in women randomized to postmenopausal hormone therapy:
results from a pilot study. Breast Cancer Res 2005, 7:R336-344.
22. Maskarinec G, Lurie G, Williams AE, Le Marchand L: An investigation of
mammographic density and gene variants in healthy women. Int J
Cancer 2004, 112:683-688.
23. van Duijnhoven FJ, Bezemer ID, Peeters PH, Roest M, Uitterlinden AG,
Grobbee DE, van Gils CH: Polymorphisms in the estrogen receptor alpha
gene and mammographic density. Cancer Epidemiol Biomarkers Prev 2005,
14:2655-2660.
24. Warren R, Skinner J, Sala E, Denton E, Dowsett M, Folkerd E, Healey CS,
Dunning A, Doody D, Ponder B, Luben RN, Day NE, Easton D: Associations
among mammographic density, circulating sex hormones, and
polymorphisms in sex hormone metabolism genes in postmenopausal
women. Cancer Epidemiol Biomarkers Prev 2006, 15:1502-1508.
25. Lillie EO, Bernstein L, Ingles SA, Gauderman WJ, Rivas GE, Gagalang V,
Krontiris T, Ursin G: Polymorphism in the androgen receptor and
mammographic density in women taking and not taking estrogen and
progestin therapy. Cancer Res 2004, 64:1237-1241.
26. Chambo D, Kemp C, Costa AM, Souza NC, Guerreiro da Silva ID:
Polymorphism in CYP17, GSTM1 and the progesterone receptor genes
and its relationship with mammographic density. Brazilian journal of
medical and biological research = Revista brasileira de pesquisas medicas e
biologicas/Sociedade Brasileira de Biofisica [et al] 2009, 42:323-329.
27. Crandall CJ, Sehl ME, Crawford SL, Gold EB, Habel LA, Butler LM, Sowers MR,
Greendale GA, Sinsheimer JS: Sex steroid metabolism polymorphisms and
mammographic density in pre- and early perimenopausal women. Breast
Cancer Res 2009, 11:R51.
28. Vachon CM, Sellers TA, Carlson EE, Cunningham JM, Hilker CA, Smalley RL,
Schaid DJ, Kelemen LE, Couch FJ, Pankratz VS: Strong evidence of a
genetic determinant for mammographic density, a major risk factor for
breast cancer. Cancer Res 2007, 67:8412-8418.
29. Qureshi SA, Couto E, Hilsen M, Hofvind S, Wu AH, Ursin G: Mammographic
density and intake of selected nutrients and vitamins in Norwegian
women. Nutr Cancer 2011, 63:1011-1020.
30. Qureshi SA, Couto E, Hofvind S, Wu AH, Ursin G: Alcohol intake and
mammographic density in postmenopausal Norwegian women. Breast
Cancer Res Treat 2012, 131:993-1002.
31. Couto E, Qureshi SA, Hofvind S, Hilsen M, Aase H, Skaane P, Vatten L,
Ursin G: Hormone therapy use and mammographic density in
postmenopausal Norwegian women. Breast Cancer Res Treat 2012,
132:297-305.
32. Hofvind S, Geller B, Vacek PM, Thoresen S, Skaane P: Using the European
guidelines to evaluate the Norwegian Breast Cancer Screening Program.
Eur J Epidemiol 2007, 22:447-455.
33. Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M,
Siozon CC, Pike MC: Mammographic density and breast cancer in three
ethnic groups. Cancer Epidemiol Biomarkers Prev 2003, 12:332-338.
34. Stone J, Ding J, Warren RM, Duffy SW, Hopper JL: Using mammographic
density to predict breast cancer risk: dense area or percentage dense
area. Breast Cancer Res 2010, 12:R97.
35. IHMP. [http://www.hapmap.org].
36. Edlund CK, Lee WH, Li D, Van Den Berg DJ, Conti DV: Snagger: a user-
friendly program for incorporating additional information for tagSNP
selection. BMC Bioinformatics 2008, 9:174.
37. Fransen L, Muller R, Marmenout A, Tavernier J, Van der Heyden J,
Kawashima E, Chollet A, Tizard R, Van Heuverswyn H, Van Vliet A: Molecular
cloning of mouse tumour necrosis factor cDNA and its eukaryotic
expression. Nucleic Acids Res 1985, 13:4417-4429.
38. Kriegler M, Perez C, DeFay K, Albert I, Lu SD: A novel form of TNF/
cachectin is a cell surface cytotoxic transmembrane protein:
ramifications for the complex physiology of TNF. Cell 1988, 53:45-53.
39. Yang Y, Feng R, Bi S, Xu Y: TNF-alpha polymorphisms and breast cancer.
Breast Cancer Res Treat 2011, 129:513-519.
40. Reeves KW, Weissfeld JL, Modugno F, Diergaarde B: Circulating levels of
inflammatory markers and mammographic density among
postmenopausal women. Breast Cancer Res Treat 2011, 127:555-563.
41. Dooley TP, Mitchison HM, Munroe PB, Probst P, Neal M, Siciliano MJ,
Deng Z, Doggett NA, Callen DF, Gardiner RM: Mapping of two phenol
sulphotransferase genes, STP and STM, to 16p: candidate genes for
Batten disease. Biochem Biophys Res Commun 1994, 205:482-489.
Ellingjord-Dale et al. Breast Cancer Research 2012, 14:R135
http://breast-cancer-research.com/content/14/5/R135
Page 9 of 10
42. Dumas I, Diorio C: Estrogen pathway polymorphisms and
mammographic density. Anticancer research 2011, 31:4369-4386.
43. Yong M, Schwartz SM, Atkinson C, Makar KW, Thomas SS, Stanczyk FZ,
Westerlind KC, Newton KM, Holt VL, Leisenring WM, Lampe JW:
Associations between polymorphisms in glucuronidation and sulfation
enzymes and sex steroid concentrations in premenopausal women in
the United States. The J Steroid Biochem Mol Biol 2011, 124:10-18.
44. Mitrunen K, Hirvonen A: Molecular epidemiology of sporadic breast
cancer. The role of polymorphic genes involved in oestrogen
biosynthesis and metabolism. Mutat Res 2003, 544:9-41.
45. Zhao YN, Zhang W, Chen YC, Fang F, Liu XQ: Relative imbalances in the
expression of catechol-O-methyltransferase and cytochrome P450 in
breast cancer tissue and their association with breast carcinoma.
Maturitas 2012, 72:139-145.
46. Reding KW, Weiss NS, Chen C, Li CI, Carlson CS, Wilkerson HW, Farin FM,
Thummel KE, Daling JR, Malone KE: Genetic polymorphisms in the
catechol estrogen metabolism pathway and breast cancer risk. Cancer
Epidemiol Biomarkers Prev 2009, 18:1461-1467.
47. Evans AM, Petersen JW, Sekhon GS, DeMars R: Mapping of prolactin and
tumor necrosis factor-beta genes on human chromosome 6p using
lymphoblastoid cell deletion mutants. Somat Cell Mol Genet 1989,
15:203-213.
48. Bachelot A, Binart N: Reproductive role of prolactin. Reproduction 2007,
133:361-369.
49. Clevenger CV, Furth PA, Hankinson SE, Schuler LA: The role of prolactin in
mammary carcinoma. Endocr Rev 2003, 24:1-27.
50. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A,
Trivin C, Postel-Vinay MC, Kuttenn F, Kelly PA: Increased expression of
prolactin receptor gene assessed by quantitative polymerase chain
reaction in human breast tumors versus normal breast tissues. J Clin
Endocrinol Metab 1998, 83:667-674.
51. Ginsburg E, Vonderhaar BK: Prolactin synthesis and secretion by human
breast cancer cells. Cancer Res 1995, 55:2591-2595.
52. Gill S, Peston D, Vonderhaar BK, Shousha S: Expression of prolactin
receptors in normal, benign, and malignant breast tissue: an
immunohistological study. J Clin Pathol 2001, 54:956-960.
53. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM: Prolactin
acts as a potent survival factor for human breast cancer cell lines. Br J
Cancer 2004, 91:305-311.
54. Nyante SJ, Faupel-Badger JM, Sherman ME, Pfeiffer RM, Gaudet MM, Falk RT,
Andaya AA, Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK,
Chanock S, Garcia-Closas M, Figueroa JD: Genetic variation in PRL and
PRLR, and relationships with serum prolactin levels and breast cancer
risk: results from a population-based case-control study in Poland. Breast
Cancer Res 2011, 13:R42.
55. Ma H, Henderson KD, Sullivan-Halley J, Duan L, Marshall SF, Ursin G, Horn-
Ross PL, Largent J, Deapen DM, Lacey JV Jr, Bernstein L: Pregnancy-related
factors and the risk of breast carcinoma in situ and invasive breast
cancer among postmenopausal women in the California Teachers Study
cohort. Breast Cancer Res 2010, 12:R35.
56. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C,
Rosner B, Speizer FE: Plasma prolactin levels and subsequent risk of
breast cancer in postmenopausal women. J Natl Cancer Inst 1999,
91:629-634.
57. Kalleinen N, Polo-Kantola P, Irjala K, Porkka-Heiskanen T, Vahlberg T, Virkki A,
Polo O: 24-hour serum levels of growth hormone, prolactin, and cortisol
in pre- and postmenopausal women: the effect of combined estrogen
and progestin treatment. J Clin Endocrinol Metab 2008, 93:1655-1661.
doi:10.1186/bcr3337
Cite this article as: Ellingjord-Dale et al.: Polymorphisms in hormone
metabolism and growth factor genes and mammographic density in
Norwegian postmenopausal hormone therapy users and non-users.
Breast Cancer Research 2012 14:R135.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ellingjord-Dale et al. Breast Cancer Research 2012, 14:R135
http://breast-cancer-research.com/content/14/5/R135
Page 10 of 10
